Columnist Mary Shaniqua, who undergoes monthly transfusions because of sickle cell, thanks the blood donors who make it ...

There are 20 cell and gene therapies on Europe's market versus 43 in the U.S. Find out more about this ecosystem.

Those who already own the stock may retain it for some time to see if VRTX's CF sales continue to rise and how the Casgevy ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We've got lots ...

Phacilitate, a leading brand that connects advanced therapies industry leaders through inspiring conferences, vibrant communities and market intelligence, today presented Katherine A. High, M.D. with ...

CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price ...

It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

The biotech sector in 2025 presents a landscape brimming with both opportunities and challenges. The industry is being shaped ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.

Beam Therapeutics shows promise in gene therapy for sickle cell disease, but it also has high risks and market expectations.